Recently, the "National Researchers' Meeting and Project Launch Event for Phase III Clinical Trial (CTR20261984) on Bismuth-Based Quadruple Therapy with Antrazole Sodium Enteric-Coated Tablets for Helicobacter pylori Eradication," sponsored by our company, was successfully held online. The event brought together over 100 participants, including leading experts in gastroenterology nationwide, principal investigators from various clinical research centers, institutional representatives, core project team members, and partners such as SMOs. All attendees reached a consensus, jointly signaling the launch of an initiative to expand the indications for antrazole sodium enteric-coated tablets—a marketed blockbuster product—for Helicobacter pylori eradication therapy.

This study was led by Professor Chen Ye from Shenzhen Hospital of Southern Medical University as the principal investigator, in collaboration with nearly 40 renowned hospitals nationwide. The conference featured a lively discussion atmosphere, with expert representatives from multiple top-tier clinical centers across China—including Peking University First Hospital, Renji Hospital affiliated with Shanghai Jiao Tong University School of Medicine, and Nanjing First Hospital—engaging in in-depth discussions on project details. The extensive and highly specialized team involved underscores the significant industry expectations for the potential of antracetrilazole sodium in Helicobacter pylori eradication therapy.

Antrazole Sodium Enteric-Coated Tablets are a domestically developed Class 1 new drug independently researched and developed by Xuanzhu Biotech over a decade, which received approval for market launch from the National Medical Products Administration (NMPA) in June 2023 for the treatment of duodenal ulcers. Antrazole sodium is metabolized through multiple enzymes, with CYP2C19 contributing only 3.5% of its metabolism, resulting in low risk of drug interactions when used concomitantly; its innovative molecular structure enables balanced excretion via both intestinal and renal pathways, reducing renal burden. In 2026, it was recommended as the preferred long-term acid-suppressing agent for elderly patients in the "China Expert Consensus on Rational Use of Acid Suppressants in the Elderly (2026 Edition)" issued by the Chinese Medical Association.

The successful convening of this launch event has not only injected strong momentum into the lifecycle expansion of Anilazole Sodium but also demonstrated Xuanzhu Biotech's unwavering commitment to advancing research in the field of gastroenterology. Moving forward, Xuanzhu Biotech will continue to collaborate with leading clinical experts and research teams nationwide to vigorously advance the research pipeline, striving for early approval of new indications and contributing sustained innovative efforts toward promoting standardized Helicobacter pylori eradication in China.

About Xuanzhu Biology:

Xuanzhu Biotech (Stock Code: 02575.HK) is an innovative pharmaceutical company rooted in China with a global vision, focusing on major disease areas such as digestive disorders, oncology, and non-alcoholic fatty liver disease. The company is dedicated to the research, development, production, and commercialization of Class 1 new drugs based on core proprietary technologies. It boasts a top-tier R&D team, with key members possessing extensive experience in new drug development. As a cutting-edge player in commercially viable innovative drugs driven by R&D and AI empowerment, the company has established a unique product pipeline that encompasses small-molecule chemical drugs, large-molecule biologics, antibody-drug conjugates, and more—a rarity in China. Guided by unmet clinical needs, the company strives to become a leading innovative pharmaceutical enterprise with comprehensive capabilities in independent R&D, production, and sales.